Genzyme
Headquarters:
500 Kendall Street
Cambridge, MA 02142
617 252 7500
Employees: 12,000
CEO: Henri Termeer
Stock Symbol: GENZ
Website:
http://www.genzyme.com
Career Page
Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing.
Genzyme focuses on six broad areas of medicine:
Lysosomal Storage Disorders
These inherited diseases, which typically affect fewer than 10,000
people worldwide, are caused by enzyme deficiencies. Genzyme
markets four enzyme replacement products to treat these diseases,
which can be life-threatening.
Cerezyme® (imiglucerase for injection)
for Type 1 Gaucher disease.
Fabrazyme® (agalsidase beta) for Fabry disease.
Aldurazyme® (laronidase) for Mucopolysaccharidosis
I.
Myozyme® (alglucosidase alfa) for Pompe
disease.
Renal Disease
Renagel® (sevelamer hydrochloride) is Genzyme's calcium-free,
metal-free phosphate binder that reduces phosphorous levels in
patients with end-stage renal disease who are on hemodialysis.
Hectorol® (doxercalciferol) is a unique pro-hormone
vitamin D2 analog formulation indicated for the treatment of
secondary hyperparathyroidism in patients with chronic kidney
disease stages 3, 4 and 5.
Orthopaedics
Synvisc® (hylan G-F 20) is one of the world's top
therapies to treat the pain of osteoarthritis of the knee.
Carticel® (autologous cultured chondrocytes) is a
cell-based therapy to help repair damaged knee cartilage currently
marketed in the U.S.
MACI®, (Matrix-induced Autologous Chondrocyte Implantation)
is a cell-based therapy to help repair damaged knee cartilage
currently marketed in Europe and Australia.
Transplant and Immune Diseases
Thymoglobulin® (anti-thymocyte globulin, rabbit)
treats acute rejection in kidney transplant patients by suppressing
the body's natural immune response. It is also being studied
for liver transplant.
Genzyme has several products in development for immune diseases
such as multiple sclerosis and pulmonary fibrosis.
Oncology
Campath® (alemtuzumab for injection), is a
treatment for B-cell chronic lymphocytic leukemia (B-CLL). It
is also being studied in multiple sclerosis.
Clolar® (clofarabine for injection), is approved for
the treatment of children with refractory or relapsed acute lymphoblastic
leukemia. It is also being studied in adult leukemia.
Thyrogen® (thyrotropin alfa for injection), is used
in thyroid cancer follow-up because it allows patients to be
screened without having to suspend thyroid hormone therapy.
Genetics / Diagnostics
Genzyme is one of the largest providers of diagnostic testing
services in the world, with expertise in reproductive and oncology
testing. Genzyme is also a major supplier of diagnostic products,
with a focus on infectious diseases, diabetes and cardiovascular
disease.
Founded in 1981, Genzyme had revenues of $4.52 billion in 2009 and net income of $422.3 million. The company spent $865 million on research and development in 2009.
Genzyme has more than 85 locations in over 40 countries, including 17 manufacturing facilities; the company's products are available in nearly 100 countries.
The company is reportedly laying off 1,000 employees worldwide and is looking to outsource jobs and implement a hiring freeze.
Benefits
Health and Dental Insurance
Short and Long Term Disability Insurance
Life and Travel Insurance
401K plan Genzyme matches 100% for the first 2% of employee
contributions and 50% for the next 4% of contributions.
Employee Stock Purchase Plan
Vacation- 3 weeks accrued per year for the first 4 years of employment,
4 weeks accrued per year after the fourth anniversary
Eleven paid holidays per year and seven sick/personal days
Tuition Reimbursement
Various employee wellness and assistance programs
|
